Response to: 'Correspondence on 'Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis by Lee

We thank Lee1 for his comments to our research article ‘Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis’.2

In our study, included patients were likely on glucocorticoids (GCs) for their underlying autoimmune diseases (ADs), not for COVID-19-associated pneumonia and cytokine release syndrome. Hence, our data suggested the possibility of harmful effects of chronic use of GCs on the risk of developing SARS-CoV-2 infection and severe COVID-19. We were unable to analyse the therapeutic effect of GCs in patients with ADs who developed COVID-19 pneumonia. As stated in the correspondence by Lee,1 a systematic review and …

留言 (0)

沒有登入
gif